A clinical case of pregnancy of a patient with a combination of two orphan diseases: familial partial lipodystrophy type 4 and HNF1A-MODY on the background of therapy with recombinant human methionyl leptin

Lipodystrophies are a group of orphan diseases (according to different sources, the prevalence of the disease varies from 1 to 5 cases per 1,000,000 population), which can be either hereditary or acquired. Diseases of this group represent a symptom complex characterized by varying degrees of loss of adipose tissue: complete (generalized lipodystrophy) or partial (partial lipodystrophy), as well as abnormal distribution of subcutaneous fat, provided that there is no influence of alimentary factors and catabolic conditions. Lipodystrophies are characterized by metabolic changes: dyslipidemia, carbohydrate metabolism disorders, insulin resistance, metabolically associated fatty liver disease. Separately, it is worth mentioning reproductive disorders, such as polycystic ovary syndrome, infertility, miscarriage, and others. A decrease in the body’s fat content leads to a decrease in the production of the hormone leptin, which affects the hypothalamic neurons that regulate hunger and satiety, and increases energy expenditure by stimulating thermogenesis. Hypoleptinemia is the main cause of metabolic disorders associated with lipodystrophy. Currently, a recombinant analogue of human leptin has been registered — metreleptin (methionyl leptin), which improves the quality of life of patients by achieving compensation for metabolic disorders, reducing hyperphagia, and also having a beneficial effect on fertility.

HNF1A-MODY is diabetes mellitus with an autosomal dominant type of inheritance associated with heterozygous variants of the HNF1A gene, which is involved in the differentiation and functioning of the pancreas. The disease is characterized by onset at a young age, prevalence of postprandial hyperglycemia, presence of glucosuria, progressive course with a high risk of developing micro- and macrovascular complications, effectiveness of therapy with sulfonylurea drugs with the emergence of the need for insulin therapy over time.

This article presents the first clinical case in Russia demonstrating the pregnancy of a patient with a combination of two orphan diseases: familial partial lipodystrophy type 4 and MODY 3 (list of rare (orphan) diseases of the Ministry of Health of Russia, dated February 6, 2023), who received pathogenetic treatment with metreleptin before confirmation of the fact of pregnancy.

1. Sorkina EL, Tiulpakov AN. Inherited and acquired lipodystrophies: molecular-genetic and autoimmune mechanisms. Obesity and metabolism. 2018;15(1):39-42. (In Russ.) doi: https://doi.org/10.14341/omet2018139-42

2. Patni N, Garg A. Lipodystrophy for the DiabetologistWhat to Look For. Curr Diab Rep. 2022;22(9):461-470. doi: https://doi.org/10.1007/s11892-022-01485-w

3. Hussain I, Patni N, Garg A. Lipodystrophies, dyslipidaemias and atherosclerotic cardiovascular disease. Pathology. 2019;51(2):202-212. doi: https://doi.org/10.1016/j.pathol.2018.11.004

4. Ryzhkova OP, Kardymon OL, Prohorchuk EB, et al. I. Guidelines for the interpretation of massive parallel sequencing variants (update 2018, v2). Medical Genetics. 2019;18(2):3-23. (In Russ.) doi: https://doi.org/10.25557/2073-7998.2019.02.3-23

5. Cook K, Adamski K, Gomes A, et al. Effects of Metreleptin on Patient Outcomes and Quality of Life in Generalized and Partial Lipodystrophy. J Endocr Soc. 2021 Feb 16;5(4):bvab019. doi: https://doi.org/10.1210/jendso/bvab019

6. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline. J Clin Endocrinol Metab. 2016;101(12):4500-4511. doi: https://doi.org/10.1210/jc.2016-2466

7. von Schnurbein J, Zorn S, Nunziata A, et al. Classification of Congenital Leptin Deficiency. J Clin Endocrinol Metab. 2024;109(10):2602-2616. doi: https://doi.org/10.1210/clinem/dgae149

8. Joy TR, Hegele RA. Prevalence of reproductive abnormalities among women with familial partial lipodystrophy. Endocr Pract. 2008;14(9):1126-32. doi: https://doi.org/10.4158/EP.14.9.1126

9. Gambineri A, Zanotti L. Polycystic ovary syndrome in familial partial lipodystrophy type 2 (FPLD2): basic and clinical aspects. Nucleus. 2018;9(1):392-397. doi: https://doi.org/10.1080/19491034.2018.1509659

10. Musso C, Cochran E, Javor E, et al. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metabolism. 2005;54(2):255-63. doi: https://doi.org/10.1016/j.metabol.2004.08.021

11. Lungu AO, Zadeh ES, Goodling A, et al. Insulin resistance is a sufficient basis for hyperandrogenism in lipodystrophic women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2012;97(2):563-7. doi: https://doi.org/10.1210/jc.2011-1896

12. Abel BS, Muniyappa R, Stratton P, et al. Effects of Recombinant Human Leptin (Metreleptin) on Nocturnal Luteinizing Hormone Secretion in Lipodystrophy Patients. Neuroendocrinology. 2016;103(3-4):402-7. doi: https://doi.org/10.1159/000439432

13. Mosbah H, Vatier C, Andriss B, et al. Patients’ perspective on the medical pathway from first symptoms to diagnosis in genetic lipodystrophy. Eur J Endocrinol. 2024;190(1):23-33. doi: https://doi.org/10.1093/ejendo/lvad169

14. Vantyghem MC, Vincent-Desplanques D, Defrance-Faivre F, et al. Fertility and obstetrical complications in women with LMNArelated familial partial lipodystrophy. J Clin Endocrinol Metab. 2008;93(6):2223-9. doi: https://doi.org/10.1210/jc.2007-2521

15. Patni N, Garg A. Congenital generalized lipodystrophies--new insights into metabolic dysfunction. Nat Rev Endocrinol. 2015;11(9):522-34. doi: https://doi.org/10.1038/nrendo.2015.123

16. Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin’s vital role in reproduction [published correction appears in Obstet Gynecol. 2013 Jul;122(1):160]. Obstet Gynecol. 2012;119(2 Pt 2):452-455. doi: https://doi.org/10.1097/AOG.0b013e31822cecf7

17. Fourman LT, Lima JG, Simha V, et al. A rapid action plan to improve diagnosis and management of lipodystrophy syndromes. Front Endocrinol (Lausanne). 2024;15:1383318. doi: https://doi.org/10.3389/fendo.2024.1383318

18. Myalept [Internet]. Summary of Product Characteristics. 2020 [cited 6 Jul 2020]. Available from: https://www.ema.europa.eu/en/documents/product-information/myalepta-epar-product-information_en.pdf

19. US Clinical Trials Registry [интернет]. Clinical Trial NCT05419037 «Natural History of Pregnancy and Pregnancy Outcomes in Metreleptin-Treated vs Untreated Subjects With Lipodystrophy» [доступ от 23.10.2024]. Доступно по ссылке: https://ichgcp.net/clinical-trials-registry/NCT05419037